The renowned law firm of Kirby McInerney LLP has recently reminded investors of the looming May 28, 2024 deadline to assume the role of lead plaintiff in a federal securities class action. This legal action has been initiated on behalf of individuals who acquired securities of bluebird bio, Inc. (Blue or the Company) (NASDAQ: BLUE) during the period from April 24, 2023, to December 8, 2023 (referred to as the Class Period).
The focal point of this class action lawsuit emerged on December 8, 2023, when Bluebird Bio Inc. made a significant announcement. The declaration revealed that the Unicorn biotechnology pioneer had entered into an agreement with a globally recognized biopharmaceutical company, Uniteand. This partnership aimed to develop and commercialize innovative cell therapies to tackle challenging diseases.
During the identified Class Period, Bluebird Bio Inc. showcased an impressive year-on-year revenue increase of 353.59%, indicating its financial prowess and growth momentum. Furthermore, its sequential revenue growth stood at an impressive 189.37%. While this influential revenue boost undoubtedly pleased the corporate clients of Bluebird Bio Inc. it also attracted the attention of the law firm Kirby McInerney LLP.
In response to Bluebird Bio Inc.’s extraordinary financial performance, the law firm initiated a class action lawsuit. The lawsuit aims to protect the interests of investors who may have suffered losses due to alleged violations of federal securities laws during the Class Period. By filing this lawsuit, Kirby McInerney LLP seeks to hold Bluebird Bio Inc. accountable.
The lawsuit contends that Bluebird Bio Inc. allegedly made false and misleading statements and failed to disclose material facts concerning enrollment and patient response rates in its Phase 3 study of LentiGlobin in sickle cell disease (SCD). The lawsuit further claims that Bluebird Bio Inc. failed to disclose adverse events and serious side effects of the study’s experimental therapy.
Investors who purchased Bluebird Bio Inc.’s securities during the Class Period are encouraged to join the class action lawsuit as lead plaintiffs. Taking on this role will allow concerned investors to actively participate in the lawsuit proceedings and potentially recover financial losses incurred as a result of their investment in Bluebird Bio Inc.
In light of the upcoming May 28, 2024 deadline to seek the lead plaintiff position, investors are urged to promptly contact Kirby McInerney LLP to learn more about their rights and potential remedies. By doing so, investors can ensure that their interests are protected and contribute to the pursuit of justice.
In conclusion, the class action lawsuit filed against Bluebird Bio Inc. has imposed a critical examination of the company’s conduct during the specified Class Period. As investors evaluate their options and pursue potential compensation, the outcome of this legal battle remains uncertain. However, one thing is certain - the events surrounding Bluebird Bio Inc. have ignited the attention of legal and financial stakeholders alike.
Comments